Sale!

TELAML ALL Test Cost

Original price was: 1,400 د.إ.Current price is: 1,050 د.إ.

-25%

The “TELAML ALL Test” is a specialized diagnostic procedure designed to identify the TEL-AML1 gene fusion, which is commonly associated with acute lymphoblastic leukemia (ALL). This genetic anomaly is crucial for the diagnosis, prognosis, and management of ALL, a type of cancer that affects the white blood cells and can progress rapidly if left untreated. The test involves analyzing the patient’s DNA to detect the presence of the TEL-AML1 fusion gene, which can influence treatment decisions and help predict the patient’s response to therapy.

Performed at DNA Labs UAE, a reputable facility known for its advanced diagnostic technologies and expert staff, the test ensures accuracy and reliability. The cost of the TELAML ALL Test is set at 1050 AED, making it a valuable investment for individuals seeking comprehensive insights into their health status concerning acute lymphoblastic leukemia. By opting for this test at DNA Labs UAE, patients and healthcare providers can access crucial genetic information that plays a significant role in tailoring treatment strategies for optimal outcomes.

Home  Sample collection service available

  • 100% accuaret Test Results
  • Ranked as Most trusted Genetic DNA Lab
  • This test is not intended for medical diagnosis or treatment
Guaranteed Safe Checkout

TEL/AML ALL Test Cost AED 1050.0 – Symptoms, Diagnosis, and Treatment

Test Name: TEL/AML ALL Test

Components: Sodium Heparin Vacutainer (2ml)

Price: 1050.0 AED

Sample Condition: Bone Marrow / Peripheral blood

Report Delivery: 3-4 days

Method: FISH

Test Type: Genetics

Doctor: Oncology

Test Department:

Pre Test Information: TEL/AML (ALL) can be done with a Doctor’s prescription. Prescription is not applicable for surgery and pregnancy cases or people planning to travel abroad.

Test Details

TEL/AML (ALL) refers to a specific subtype of acute lymphoblastic leukemia (ALL) known as TEL-AML1 or ETV6-RUNX1. It is the most common genetic abnormality found in childhood ALL, accounting for approximately 20% of cases.

TEL/AML is caused by a chromosomal translocation between the TEL (ETV6) gene on chromosome 12 and the AML1 (RUNX1) gene on chromosome 21. This translocation results in the fusion of the two genes, creating a hybrid gene called TEL-AML1 or ETV6-RUNX1.

The presence of the TEL-AML1 fusion gene is associated with a favorable prognosis in pediatric ALL. Children with TEL/AML (ALL) tend to have a higher overall survival rate and a lower risk of relapse compared to other subtypes of ALL.

However, treatment protocols for TEL/AML (ALL) may vary depending on the specific characteristics of the individual patient and the risk stratification. Generally, treatment involves chemotherapy, which may include multiple phases such as induction, consolidation, and maintenance therapy. In some cases, additional treatments such as radiation therapy or stem cell transplantation may be considered.

Overall, TEL/AML (ALL) is a subtype of acute lymphoblastic leukemia that is characterized by a specific genetic abnormality and has a relatively favorable prognosis in pediatric patients.

Test Name TELAML ALL Test
Components Sodium Heparin Vacutainer (2ml)
Price 1050.0 AED
Sample Condition Bone Marrow \/ Peripheral blood
Report Delivery 3-4 days
Method FISH
Test type Genetics
Doctor Oncology
Test Department:
Pre Test Information TEL/AML (ALL) can be done with a Doctors prescription. Prescription is not applicable for surgery and pregnancy cases or people planing to travel abroad.
Test Details

TEL/AML (ALL) refers to a specific subtype of acute lymphoblastic leukemia (ALL) known as TEL-AML1 or ETV6-RUNX1. It is the most common genetic abnormality found in childhood ALL, accounting for approximately 20% of cases.

TEL/AML is caused by a chromosomal translocation between the TEL (ETV6) gene on chromosome 12 and the AML1 (RUNX1) gene on chromosome 21. This translocation results in the fusion of the two genes, creating a hybrid gene called TEL-AML1 or ETV6-RUNX1.

The presence of TEL-AML1 fusion gene is associated with a favorable prognosis in pediatric ALL. Children with TEL/AML (ALL) tend to have a higher overall survival rate and a lower risk of relapse compared to other subtypes of ALL.

However, treatment protocols for TEL/AML (ALL) may vary depending on the specific characteristics of the individual patient and the risk stratification. Generally, treatment involves chemotherapy, which may include multiple phases such as induction, consolidation, and maintenance therapy. In some cases, additional treatments such as radiation therapy or stem cell transplantation may be considered.

Overall, TEL/AML (ALL) is a subtype of acute lymphoblastic leukemia that is characterized by a specific genetic abnormality and has a relatively favorable prognosis in pediatric patients.